Company Management

Redenlab

Biotechnology Research 585 Collins St 33 employees

Employees: 33
Contacts: 3
Emails: 3

redenlab.com LinkedIn

Redenlab Overview

Headquarters: 585 Collins St
Website: redenlab.com
Industry: Biotechnology Research
Employees: 33
Founded: 2017
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

neuroscience speech language dysphagia clinical trials analysis pipeline biometrics neurology acoustics science technology biomarkers

About Redenlab

Redenlab Inc is an industry leading neuroscience focussed tech bio. We use speech and language biometrics to improve decision-making in clinical trials. Whether the trials take place in clinic, at home, or virtually, our tests are sensitive and reliable, accurately detecting subtle changes caused by disease or treatment. Our speech software and hardware solutions meet all the regulatory requirements for data security and integrity in clinical trials, including 21 CFR Part 11 and HIPAA. Follow us to find out more about our groundbreaking projects and explore the future of speech analysis at www.redenlab.com.

Redenlab Contact Details

People in AeroLeads: 4
With contact data: 3
Email contacts: 3; 75.0% coverage

Redenlab Org Chart

Sample employees and titles

Name	Title	Location	Contact
Dr. Amir Lahav	Game-changing Advisor in Health AI	Greater Boston, United States	Email
Devon Borysiewicz	Vice President of Technology	Gladstone, Queensland, Australia	Email
James Fletcher	Investment Adviser at Evans & Partners	Greater Melbourne Area, Australia	Email
Roger L. O'sullivan	General Counsel, Corporate Secretary		View